Costo ed efficacia delle nuove strategie terapeutiche nell epatite cronica C
|
|
- Robyn Perkins
- 5 years ago
- Views:
Transcription
1 Costo ed efficacia delle nuove strategie terapeutiche nell epatite cronica C Rome, June 25, 2015 Mario Angelico Liver Unit, Università Tor Vergata, Roma
2
3 Where do we come from? A priori probability of response to dual (Peg-IFN + ribavirin) therapy SVR Virological Profile 24 to 72 weeks 80-95% HCV-2 Easy-to-Treat 75-80% HCV-3 Low viremia 60-70% HCV-3 High viremia 50-60% HCV-4 50% HCV-1 Low viremia 30-35% HCV-1 High viremia Difficult-to-Treat
4 DAA (Directly Acting Agents)
5 The HCV replication complex A polyprotein of approx 3100 aminoacids 6 nonstructural HCV proteins (incl. enzymes essential for HCV life cycle)
6
7 Birth and premature death of 1st wave DAAs (protease NS3/4 inhibitors) Boceprevir Telaprevir
8 Birth and premature death of 1st wave DAAs (protease NS3/4 inhibitors) Potent, but. Boceprevir Telaprevir Severe side effects Too many pills Potentially harmful drug-drug interactions Need of peg-ifn and ribavirin coadministration Still long-treatment schedules
9 Virological targets 2nd wave DAAs Approved NS5B NS5A NS3/4A
10 DAAs as components of new treatment paradigm for hepatitis C Peg-IFN + RBV (SOC) IFN-based 1 x DAA + SOC 2 x DAAs + SOC Prospect of shorter treatment duration for a greater proportion of patients IFN-free IFN-free Time DAA=direct-acting antiviral; SOC=standard of care
11 Sofosbuvir (SOF, GS-7977) HCV-specific uridine nucleotide NS5B polymerase inhibitor (chain terminator) Potent antiviral activity against HCV genotypes 1 6 High barrier to resistance Once-daily, oral, 400-mg tablet Favorable clinical pharmacology profile No food effect Renally cleared - limited potential for drug interactions No CYP3A/4 metabolism H 3 C H 3 C CH 3 O Well-tolerated with an excellent safety profile in clinical studies O O HN P O O HO O O NH N O CH 3 F
12 Kinetics of HCV-RNA decay following administration of SOF +/- RBV in 18 patients Unpublished, Tor Vergata Liver and Virology Units, 2014 Patients with severe HCVrecurrence post-olt (n=11) Patients awaiting for OLT (n=7) 7.0 No RBV + RBV No RBV + RBV Log HCV-RNA (IU/ml) HCV-genotypes: GT-1a = 2 GT-1b = 3 GT-2 =1 GT-3 = 3 GT-4 = 2 HCV-genotypes: GT-1a = 1 GT-1b = 3 GT-3 = LLoQ LLoD Baseline 1w 2w 3w 4w 5w 6w Baseline 1w 2w 3w 4w 5w 6w OLT, orthotopic liver transplantation; RBV, ribavirin; IU, international units; GT, genotype; LLOQ, lower limit of quantification (12 IU/ml); LLOD, lower limit of detection.
13 SOF Phase 3 Study Designs GT 1/4/5/6 Week No response-guided therapy NEUTRINO Treatment-Naïve SOF + PegIFN + RBV, n=327 SVR12 SVR24 FISSION Treatment-Naïve SOF + RBV, n=256 PegIFN + RBV, n=243 FUSION Treatment-Experienced SVR12 SOF + RBV, n=103 PBO SVR12 SVR12 GT 1/2/3 All Oral Therapy SOF + RBV, n=98 POSITRON PegIFN-Unable SOF + RBV, n=207 PBO, n=71 VALENCE Treatment-Naïve and Treatment-Experienced GT2: SOF + RBV, n=73 GT3: SOF + RBV, n=250 PHOTON-1 Treatment-Naïve SOF + RBV, n=68 SOF + RBV, n=114 SVR12 SVR12 SVR12 SVR12 SVR12 SVR12 SOF 400 mg/d; PegIFN 180 μg/wk; RBV mg/d for SOF+RBV arms and 800 mg/d for PegIFN+RBV arm
14 Rates of Sustained Virologic Response in the NEUTRINO and FISSION Studies, According to Subgroup and Baseline Factors. Lawitz E et al. N Engl J Med 2013;368:
15 SOF Phase 3 Fibrosis Analysis SVR12 Rates in GT 1, 4, 5, 6 (NEUTRINO) SVR12 Rates by Biopsy Fibrosis Stage (n=232) SVR12 Rates by FibroTest Stage (n=323) SVR12 (%) ( ) n = 16/16 124/137 34/38 32/41 n = 76/78 101/105 46/54 68/86 16/16 124/137 34/38 32/41 076/78 26/29 75/76 46/54 68/86 63/65 23/26 66/67 41/49 64/81 Treating at earlier stages of fibrosis is associated with higher response! Patel K, et al. AASLD Washington, DC. #1093
16 Simeprevir plus sofosbuvir w/wo ribavirin, to treat HCV-G1-infected previous non-responders and naïve patients: The COSMOS randomized study Lawitz et al, Lancet 2014; 384: Cohort 1 Patients with null response to previous treatments (METAVIR F0-F2) Coorte 2 Patients with null response to previous treatment and naive patients with severe fibrosis (METAVIR F3 o F4) 12 weeks treatment SMV+SOF+RBV (n=27) SMV/SOF (n=14) SMV/SOF+RBV (n=27) SMV/SOF (n=14) SVR 4 26 (96%) 13 (93%) 26 (96%) 14 (100) SVR (96%) 13 (93%) 25 (92%) 12 (93%)
17 TURQUOISE II STUDY - published on April 12, 2014, at NEJ
18 Ledipasvir/Sofosbuvir: A Single Tablet Ledipasvir Regimen (STR) ( Harvoni ) Once-daily, oral, 90-mg NS5A inhibitor LDV NS5A inhibitor O H O N O N N N H F F H N H N N O N O H O Sofosbuvir Once-daily, oral, 400-mg NS5B inhibitor H 3 C H 3 C O O CH 3 O HN P O O O O N NH O CH 3 HO F SOF nucleotide NS5B polymerase inhibitor Ledipasvir/Sofosbuvir FDC Once-daily, oral, fixed-dose LDV NS5A LDV inhibitor NS5A inhibitor FDA Approval 10 Oct 2014 European Approval 18 Nov 2014 SOF SOF SOF NS5B SOF nucleotide nucleotide polymerase polymerase polymerase nucleotide inhibitor inhibitor inhibitor polymerase inhibitor
19 ION-1 & ION-2 published on April 12, 2014, at NEJM.org
20 LDV/SOF ± RBV: Compensated Cirrhosis Results: SVR12 by Treatment Regimen Overall SVR wk wk Duration 24 wk Treatment Naïve 98% 97% 99% Treatment Experienced 95% 94% 98% Regimen LDV/SOF LDV/SOF + RBV 96% 99% 95% 96% LDV/SOF 12 wk 96% 90% Duration/ ± RBV LDV/SOF + RBV 12 wk LDV/SOF 24 wk 98% 97% 96% 98% LDV/SOF + RBV 24 wk 100% 100% Bourliere, AASLD, 2014, Oral #82 Among TE cirrhotic patients, 12 weeks of LDV/SOF + RBV resulted in similar SVR rates to 24 weeks of LDV/SOF alone
21 LDV/SOF ± RBV: Compensated Cirrhosis Results: SVR12 by Baseline Characteristics AA Treatment Treatment Naïve Treatment Experienced Treatment Experienced Overall SVR12 98% 95% Genotype GT 1a GT 1b 98% 97% 95% 96% Age <65 years 65 years 98% 94% 95% 98% PI Failure Yes No 96% 95% Bourliere, AASLD, 2014, Oral #82
22 2013 AASLD Meeting, Washington, oral presentation Gastroenterology 2015; 148: Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection After Liver Transplantation Michael P. Curry, Xavier Forns, Raymond Chung, Norah Terrault, Robert Brown Jr, Jonathan M. Fenkel, Fredric Gordon, Jacqueline O Leary, Alexander Kuo, Thomas Schiano, Gregory Everson, Eugene Schiff, Alex Befeler, John G. McHutchison, William T. Symonds, Jill Denning, Lindsay McNair, Sarah Arterburn, Dilip Moonka, Edward Gane, Nezam Afdhal
23 Pre-Transplant SOF + RBV to Prevent HCV Recurrence Post-Transplant No Recurrence vs. Recurrence in GT 1 4 Days Continuously TND Prior to Transplant: PTVR vs. Recurrence in GT 1 4 * No Recurrence (n=28) Recurrence (n=10) 1/25 patients had recurrence after > 4 weeks continuous TND Median days TND No recurrence: 95 Recurrence: 5.5 p < Days with HCV RNA Continuously TND Prior to Liver Transplant *3 patients with recurrent HCV had 0 consecutive days TND before transplant. Curry MP, et al.
24 Hepatology, 2015 EASL, 2014 Sofosbuvir Compassionate Use Program for Patients with Severe Recurrent Hepatitis C Including Fibrosing Cholestatic Hepatitis Following Liver Transplantation Xavier Forns 1, Martín Prieto 2, Michael Charlton 3, John G. McHutchison 4, William T. Symonds 4, Diana Brainard 4, Jill Denning 4, Theo Brandt-Sarif 4, Paul Chang 4, Valerie Kivett 4, Robert J. Fontana 5, Thomas F. Baumert 6, Audrey Coilly 7, Lluís Castells 8, François Habersetzer 6 1 Liver Unit, IDIBAPS, CIBEREHD, Hospital Clinic, Barcelona, Spain; 2 Hepatology Unit, CIBEREHD, Hospital Universitari i Politècnic La Fe, Valencia, Spain; 3 Mayo Clinic, Rochester, MN, USA; 4 Gilead Sciences, Foster City, CA, USA; 5 University of Michigan, Ann Arbor, MI, USA; 6 Hôpitaux Universitaires de Strasbourg, Inserm U 1110, Strasbourg, France; 7 Centre Hépato-Bilaire, Hôpital Paul Brousse, Inserm UMR-S785, Villejuif, France; 8 Liver Unit Internal Medicine Department, CIBEREHD, Hospital Universitari Vall Hebron, Barcelona International Liver Congress 2014, London, UK
25 Results: Patient Disposition Severe acute hepatitis/early recurrence (<12 months from liver transplant with typical biochemical and histological findings) n=48 Post transplant compensated and decompensated cirrhosis (liver biopsy (F4) or clinical decompensation) n=56 Early term due to AE n=7 Liver transplant n=12 SOF Compassionate Use Program SOF + RBV ± PEG n=104 Death n=13 Completed weeks treatment n=72 25
26 Results: Overall Virologic Response 8/93 4/93 4/85 13/85 15/85 Patients (%) 26
27 Results: Clinical Outcomes Patients (%) All patients who received 1 dose of SOF are included *Significant decrease in hepatic encephalopathy, improvement or disappearance of ascites, or improvement in liver-related laboratory values. 27
28 Laboratory Results: MELD Score Change From Baseline to Follow-Up Week 4 CPT B CPT C 12 wk (n=30)* 24 wk (n=29)* 12 wk (n=23)* 24 wk (n=26)* (+10) n=5 n=5 n=2 n=3 *Missing FU-4: n=2 CPT B 12 wk; n=4 CPT B 24 wk; n=2 CPT C 12 wk; n=7 CPT C 24 wk. (-8) 28
29 SVR for different IFN-free regimens in F3/F4 (compensated) Genotype 2 patients SOF + RBV Naive SOF + SMV ± RBV SOF + DCV ± RBV SOF/LDV ± RBV ABT450/r/ombitasvir + dasabuvir + RBV SVR (%) Size of the red circle corresponds to the number of patients enrolled into the study. Adapted from Lens S, et al. Sem Liver Disease 2014; 34:58 71.
30 SVR for different IFN-free regimens in F3/F4 (compensated) Genotype 1 and 4 patients SOF + RBV Naive SOF + SMV ± RBV SOF + DCV ± RBV SOF/LDV ± RBV Naive and experienced ABT450/r/ombitasvir + dasabuvir + RBV SVR (%) Size of the red circle corresponds to the number of patients enrolled into the study. Adapted from Lens S, et al. Sem Liver Disease 2014; 34:58 71.
31 SVR for different IFN-free regimens in non cirrhotic Genotype 3 patients SOF + RBV SOF + SMV ± RBV SOF + DCV ± RBV SOF/LDV ± RBV Naive and experienced ABT450/r/ombitasvir + dasabuvir + RBV SVR (%) Size of the red circle corresponds to the number of patients enrolled into the study. Adapted from Lens S, et al. Sem Liver Disease 2014; 34:58 71.
32 SVR for different IFN-free regimens in cirrhotic Genotype 3 patients SOF + RBV SOF + SMV ± RBV SOF + DCV ± RBV SOF/LDV ± RBV Naive and experienced ABT450/r/ombitasvir + dasabuvir + RBV SVR (%) Size of the red circle corresponds to the number of patients enrolled into the study. Adapted from Lens S, et al. Sem Liver Disease 2014; 34:58 71.
33 HCV Regimens in US, Canada and Germany, 2014 SOF/SMV/RBV 14.9% SOF/PEG/R BV 23.1% SOF/RBV 8.8% SOF SMV 1.37% SOF/PEG/RBV 0.9% Genotype 1 SOF/PEG/RBV 8.5% SOF/RBV 99.1% Genotype 2 Genotype 3 SOF/RBV 91.5% N=1994 SOF Containing Regime
34 From December, 2014 to April, 2015 in US
35 SOF PEG RBV Demographics SOF RBV SOF SMV SOF SMV RBV Total* n(%) N=384 N=667 N=784 N=228 N=2063 MALE 253(66.2) 422 (63.6) 478 (62.0) 147 (65.3) 1300 (63.7) MEAN Age, y (range) 53.9 (23-79) 56.9 (21-82) 59.5 (20-83) 58.8 (29-80) 57.6 (20-83) Age (8.1) 131 (19.7) 190 (24.6) 40 (17.8) 392 (19.2) CAUCASIAN 270 (70.3) 539 (80.8) 584 (74.5) 177 (77.6) 1570 (76.1) BLACK 68 (17.8) 37 (5.6) 96 (12.5) 33 (14.7) 234 (11.5) TREATMENT STATUS NAIVE 211 (54.9) 371 (55.6) 318 (40.6) 82 (36.0) 982 (47.6) EXPERIENCED 172 (44.8) 296 (44.4) 465 (59.3) 144 (63.2) 1077 (52.2) PI FAILURE 47 (27.3) 25 (8.4) 76 (24.8) 45 (31.3) 193 (17.9) CIRRHOSIS 120 (31.3) 302 (45.3) 440 (56.1) 137 (60.1) 999 (48.4) Hx Decompensation 12 (11.4) 136 (49.5) 167 (44.8) 60 (50.8) 375 (43.1) MELD >10 18 (17.1) 120 (43.6) 122 (32.7) 34 (28.8) 294 (33.8) LIVER CANCER 25 (6.5) 66 (9.9) 88 (11.2) 32 (14.0) 211 (10.2) LIVER TRANSPLANT 27 (7.0) 57 (8.5) 111 (14.2) 32 (14.0) 227 (11.0) HIV 14 (3.6) 18 (2.7) 8 (1.0) 7 (3.1) 47 (2.3) 78% (253/323) of G1, non-cirrhotic, naïve had a baseline HCV RNA <6 million IU/mL *Total, patients who started therapy SOF Containing Regimen
36 HCV RNA Outcomes for SOF/SMV±RBV: Genotype 1 SOF + SMV ± RBV N=378 Latest Available HCV RNA BLOQ 91% (335/369) Latest Available HCV RNA Quantified 9% (34/369) SVR4 + evaluable 303/369 SVR4 + 89% 269/303 Prior PI Failures excluded from this analysis VBT 0.33% (1/303) Relapse 8.9% (27/303) SVR4 + No cirrhosis: 92% (113/123) Cirrhosis: 87% (156/180) Prior decomp: 75% (61/81) Non-Response 2% (6/303) Lost to f/u 0% (0/303) SVR4 + G1a: 86% (154/180) G1b: 95% (88/93) Cohort of patients with treatment start on or before 4/15/14 ; BLOQ=Below Level of Quantitation; SOF Containing Regimen
37 HCV RNA Outcomes for SOF/SMV±RBV: Genotype 1 PRIOR PI FAILURES SOF + SMV ± RBV N=72 Latest Available HCV RNA BLOQ 86% (59/69) Latest Available HCV RNA Quantified 14% (10/69) SVR4 + evaluable 54/69 SVR4 + 81% 44/54 VBT 0% (0/54) Relapse 19% (10/54) Non-Response 0% (0/54) Lost to f/u 0% (0/303) SVR4 + No cirrhosis: 85% (17/20) Cirrhosis: 79% (27/34) Cohort of patients with treatment start on or before 4/15/14 ; BLOQ=Below Level of Quantitation; SOF Containing Regimen
38 HCV RNA Outcomes for SOF + RBV: Genotype 2 SOF + RBV GT2 N=235 Latest Available HCV RNA BLOQ 91% (204/223) Latest Available HCV RNA Quantified 9% (19/223) SVR4 + evaluable 187/223 SVR4+ 90% (168/187) VBT 0.5% (1/187) Relapse 8% (14/187) Non-Response 1.1% (2/187) SVR4 Non-cirrhotic: 91% (116/128) Cirrhotic: 88% (52/59) Lost to f/u 1.1% (2/187) SOF Containing Regimens Cohort of patients with treatment start on or before 4/15/14 ; BLOQ=Below Level of Quantitation
39 Summary of efficacy of DAAs in cirrhotic patients SVR rates with DAA therapy in cirrhosis are lower than in non cirrhotic patients, especially in those with previous treatment failure or decompensation Treatment must be initiated ASAP! Strategies successful in improving SVR rates include: Longer duration of therapy Addition of ribavirin Addition of another DAA (treatment personalization?) Presence of significant portal hypertension (platelet count <80-100) may be an important predictor of reduced SVR
40 Patients and doctors expectations for HCV treatment with DAAs SVR rates >90% IFN-free treatment schedules Short treatment duration (12-24 weeks or less) All oral treatment Few pills, better once daily Lack of SAE and good tolerability High genetic barrier Possibly pan-genotypic (?)
41 Patients and doctors expectations for HCV treatment with DAAs SVR rates >90% IFN-free treatment schedules Short treatment duration (12-24 weeks or less) All oral treatment Few pills, better once daily Lack of SAE and good tolerability High genetic barrier Possibly pan-genotypic (?) Equitable access to treatment Reasonable and sustainable costs Need to identify urgency-based treatment priorities
42 2 nd wave DAA approval timeline Sofosbuvir (Sovaldi) and Simeprevir (Olysio) approved in December 2013 in Japan and US and by EMA in January 2014 Sofosbuvir (Sovaldi) approved in Italy from December 2014 Simeprevir (Olysio) approved in Italy since March 2015 Daclatasvir (Daklinza) approved in Italy in early May 2015 ABT-450, -257, 333 (Viekierax and Exviera) approved in Italy in late May 2015 (or 3D) Sofosbuvir + Ledipasvir (Harvoni) approved in Italy in late May 2015
43 HCV-infected patients admitted to reimbursement of DAA therapy according to AIFA rules, CPT Class A or B cirrhosis, with or without HCC with complete response to surgical or ablative treatments, whose prognosis is dependent on the underlying liver disease 2. Liver transplant recipients with recurrent HCV infection (with METAVIR score >2, or with fibrosing cholestatic hepatitis) 3. Chronic HCV-infection with severe extrahepatic manifestations (cryoglobulinemia, B-cell lymphoma) 4. Chronic hepatitis with fibrosis METAVIR score F3 5. MELD <25 cirrhosis and/or HCC within Milan criteria listed for liver transplant, with an expected waiting time >2 months 6. Transplant recipients of solid organs (except liver) with fibrosis METAVIR score >2 7. (Chronic hepatitis with fibrosis METAVIR score F0-F2)
44 Open issues and grey areas with DAA in 2015 Real effectiveness in decompensated cirrhosis Treatment of HCV infected patients with renal dysfunction What to do in failures to sofosbuvir and other DAAs? What residual role for ribavirin (and pegifn), if any? How to optimize treatment of G3 infected patients Predictors of SVR: what to do in slow responders? Does IL28B matter in non responders? DAA-induced delisting for liver transplant: does it improve prognosis? When should we be able to treat all infected patients (not only those deserving prioritization)? How to choose between Harvoni, Viekirax/Exviera, and SOF+SIM or SOF+DAC in the real world? Only on money constraints?
45
Gestione del paziente HCV+ con epatopatia avanzata
Gestione del paziente HCV+ con epatopatia avanzata Alghero, May 22, 2015 Mario Angelico Liver Unit, Università Tor Vergata, Roma Where do we come from? A priori probability of response to dual (Peg-IFN
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationTreating HCV After Liver Transplantation: What are the Treatment Options?
4 th OPTIMIZE WORKSHOP USING DAAs IN PATIENTS WITH CIRRHOSIS AND LIVER RECIPIENTS Treating HCV After Liver Transplantation: What are the Treatment Options? Maria Carlota Londoño, MD Liver Unit, Hospital
More informationHepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation
More informationTREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona
TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona Hepatitis C after LT Survival (%) HCV negative HCV positive Time from LT (years) HCV treatment
More informationTreatment of Hepatitis C Recurrence after Liver Transplantation. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Treatment of Hepatitis C Recurrence after Liver Transplantation Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Agenda 1. Introduction 2. Treatment options for hepatitis C recurrence after transplantation
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationIL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?
IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More informationDAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France
DAA-based treatment in cirrhotic and post-transplanted patients Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France Cirrhosis and transplantation 2 populations with similar issues Hepatic impairment
More informationTransformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
More informationTransplantation. Professor Didier. Centre Hépatobiliaire, Hépatobiliaire, C.H.B.
Treatment Treatment of of Hepatitis Hepatitis C C in in Liver Liver Transplantation Transplantation Professor Professor Didier Didier Samuel Samuel Centre Centre Hépatobiliaire, Hépatobiliaire, Inserm
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationTerapie attuali. Eradicazione di HCV e nuove prospettive:
Eradicazione di HCV e nuove prospettive: Terapie attuali Luisa Pasulo U.S.C. Gastroenterologia Epatologia e Trapiantologia Ospedale Papa Giovanni XXIII - Bergamo From Infection to liver disease Infezione
More informationTreatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy
Treatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy antonio.craxi@unipa.it Ad Board and grants: Abbvie, Achillion, BristolMyers Squibb,
More informationO. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki
O. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki Disclosures Advisory Board: Abbvie Pharmaceuticals Speaker: Gilead Sciences, Bristol-Myers Squibb Research
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationWill difficult-to-treat patients remain difficultto-treat. generation of treatments?
Will difficult-to-treat patients remain difficultto-treat with the new generation of treatments? Jordan J Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University
More informationHCV Therapy in Liver Transplant Candidate
PHC 216 HCV Therapy in Liver Professor Didier SAMUEL Transplant Candidate Dr Audrey COILLY Centre Hépato-Biliaire, Inserm 1193 Treat before orrearch afuniter? University Paris Sud A Villejuif u d r e yfrance
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationRecurrent HCV after a Pre-LTx Course of SOF/DAC:
Recurrent HCV after a Pre-LTx Course of SOF/DAC: Didier Samuel, Teresa Antonini Centre Hépato-Biliaire, Inserm Paris Sud Research Unit 1193 Hôpital Paul Brousse, Villejuif, France 3 rd Optimize Workshop,
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More informationEliminating Hepatitis C from New Zealand
Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationLiver transplantation and hepatitis C virus
Liver transplantation and hepatitis C virus Where do we come from? Where are we? Where are we going? François Durand Hépatologie & Réanimation Hépato-Digestive INSERM U1149 Hôpital Beaujon, Clichy HCV:
More informationHIV/Hepatitis C in France: data from real life cohorts LIONEL PIROTH CHU DIJON UNIVERSITY OF BURGUNDY DECEMBER LONDON
HIV/Hepatitis C in France: data from real life cohorts LIONEL PIROTH CHU DIJON UNIVERSITY OF BURGUNDY DECEMBER 2015 - LONDON The need Decreasing prevalence of chronic hepatitis C in French people living
More informationTreatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble
Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989
More informationI nuovi farmaci per HCV: frequenza della patologia, evidenze di efficacia e sicurezza, strategie di gestione. la pratica clinica
I nuovi farmaci per HCV: frequenza della patologia, evidenze di efficacia e sicurezza, strategie di gestione La revisione ii delle dll evidenze e indicazioni i iper la pratica clinica Marco Marzioni Segretario
More informationAASLD/IDSA HCV treatment guidelines. Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School
AASLD/IDSA HCV treatment guidelines Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School Disclosure Statement for Arthur Kim Grant/research support to institution, last 12 months: Gilead
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationManagement of HCV Tawesak Tanwandee
Management of HCV 2016 Tawesak Tanwandee Topics Burden of HCV in our countries Natural history and unmet need for HCV treatment Current treatment as for 2016 Conclusion Evolution from HCV infection to
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.32 Subject: Harvoni Page: 1 of 7 Last Review Date: December 3, 2015 Harvoni Description Harvoni (ledipasvir
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More informationVIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015
VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research
More informationCase 2: A 71-year-old man with cirrhosis
Case 2: A 71-year-old man with cirrhosis 1 JM, 71 year old African American male with known cirrhosis Asymptomatic apart from fatigue No prior history of decompensation Past history: Diabetes for 11 years
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: March 18, 2016 Harvoni Description Harvoni (ledipasvir
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationMassimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future
Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationHCV disease: treatment or deferral? Antonio Craxì Gastroenterologia & Epatologia, Di.Bi.M.I.S., Università di Palermo
HCV disease: treatment or deferral? Antonio Craxì Gastroenterologia & Epatologia, Di.Bi.M.I.S., Università di Palermo antonio.craxi@unipa.it Key factors in deciding to treat or wait Patient factors Urgency
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationSupplementary Material*
Supplementary Material* Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost- Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus. Ann Intern Med. doi:10.7326/m14-1152
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: December 2, 2016 Harvoni Description Harvoni (ledipasvir
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationA One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran
A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs
More informationTreatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
More informationHCV: Current SOTA of Management of Treatment Experienced Patients
HCV: Current SOTA of Management of Treatment Experienced Patients Robert G Gish MD Professor Consultant Stanford University Executive Committee: National Viral Hepatitis Roundtable Founding Member: CEVHAP
More information